MERZ-AESTHETICS
20.10.2020 12:38:06 CEST | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced that Radiesse® is celebrating ten million syringes shipped worldwide over almost twenty years. Radiesse® is a unique calcium hydroxylapatite (CaHA) injectable filler1 used for volumization, lifting and contouring, as well as skin rejuvenation by stimulating natural collagenogenesis.2,3 The product portfolio includes Radiesse® and Radiesse® Lidocaine delivering effective and natural-looking cosmetic results, distinguished by its established safety profile4 and high patient satisfaction.5
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005619/en/
“As we reflect on this milestone, we are proud of the fact that, Radiesse has proven to provide aesthetic practitioners with a unique treatment that they can administer confidently, while supporting their patients’ desired impact,” said Kristel Hectors, Head of Marketing EMEA, Merz Aesthetics. “With almost twenty years of scientific evidence and clinical experience, Radiesse is such a unique product and full of opportunities and possibilities. As we are looking ahead, we are excited for what’s to come over the next years for Radiesse.”
The milestone campaign launching under the tagline “The Power Used By Millions” reinforces the uniqueness of the product and its working mechanism. Informing health care professionals and educating patients on the uniqueness of Radiesse® , on its working mechanism and efficacy.
“Radiesse is my number one go to product because of its versatility. Radiesse plus for contouring, lifting, ligaments and volumizing. Classic Radiesse for classic indications like folds and of course hyperdiluted Radiesse for skin quality improvement,” said Jani van Loghem, MD Cosmetisch arts KNMG. “It is a biostimulatory product going beyond a hyaluronic acid: the collagen will be giving the patient the final result and it is a really nice message to the patient! That’s why I choose Radiesse.”
About Radiesse®
/Radiesse®
(+) Lidocaine
Radiesse®
is an injectable dermal filler that provides immediate volume and correction and continues to work by stimulating the body’s own natural collagen production. In addition, Radiesse activated the self-renewing potential within the skin to make the skin firm, elastic and strong. Radiesse can be tailored to individual requirements and skin condition.1,6-10
Radiesse® (+) Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). In Europe, Radiesse® (+) Lidocaine is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.1,6-10
Radiesse® / Radiesse® (+) Lidocaine is valued by doctors and patients around the world for its tolerability and safety profile. Radiesse received the CE mark for aesthetic use in Europe in 2004, with U.S. FDA approval following in 2006. In that time, Radiesse has been considered a leading minimally-invasive aesthetic treatment trusted by healthcare providers around the world. The product has been available on the market for more than fifteen years, with now 10 million syringes shipped worldwide and a clinically proven safety profile supported by more than 200 clinical studies and peer-reviewed publications.1,6-10
Radiesse is available in more than 70 countries worldwide.
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. Radiesse® is a registered trademark of Merz North America, Inc.
1 RADIESSE Instructions for Use Nov. 2017. RADIESSE® Lidocaine Instructions for Use Jun.2018.
2 Berlin AL, et al. Dermatol Surg. 2008;34(suppl 1):S64-S67.
3 Moers-Carpi M, et al. Dermatol Surg. 2007;33(suppl 2):S144-S151.
4 Van Loghem JV, et al. J Clin Aesthet Dermatol. 2015:8(1)38-49.
5 Juhász MLW, Marmur ES, Dermatol Surg. 2018;44(8)1084-93.
6 Yutskovskaya Y, et al. J Drugs Dermatol. 2014;13(9):1047-52.
7 Yutskovskaya YA, Kogan EA. J Drugs Dermatol. 2017;16(1):68-74.
8 Schachter D, et al. J Drugs Dermatol. 2016 Aug 1; 15(8): 1005-10.
9 Sundaram H, et al. Dermatol Surg. 2010;36 (suppl 3):1859-1865.
10 Schachter Science Brief: Pain Control using the Injectable Dermal Filler Radiesse (+) for the correction of Nasolabial folds. Daniel Schachter, Vince Bertucci, Nowell Solish. POSTER PRESENTATION at 13th Anti-Aging Medicine World Congress (2015), Monaco, Monte Carlo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005619/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom